Hailey-Hailey disease (HHD), also referred to as familial benign chronic pemphigus, is a rare genetic disorder that predominantly affects the skin. First described by the Hailey brothers in 1939, this condition is characterized by recurrent, painful skin lesions caused by a defect in the ATP2C1 gene. The disorder is inherited in an autosomal dominant manner, meaning individuals with an affected parent have a 50% chance of inheriting the condition. Although HHD can manifest at any age, it typically presents in the late teenage years to the third decade of life. The disease often causes significant morbidity due to the recurrent nature of the lesions and their location, which can severely impact a patient’s quality of life.

Pathophysiology and Genetic Basis

Hailey-Hailey disease results from mutations in the ATP2C1 gene, which encodes a calcium pump located in the Golgi apparatus of keratinocytes. This pump plays a crucial role in regulating calcium homeostasis and maintaining cellular adhesion. Dysfunction of the ATP2C1 gene leads to defective cell-cell adhesion in the epidermis, causing the skin to become fragile and prone to blistering. The lack of adequate cohesion between skin layers contributes to the formation of lesions, especially in areas subjected to friction and sweating.

Clinical Features

The hallmark of Hailey-Hailey disease is the development of painful, red, scaly lesions that typically appear in areas where skin rubs together, such as the armpits, groin, sides of the neck, and beneath the breasts. The initial lesions often present as fluid-filled blisters that rupture easily, leading to maceration or crusting. These lesions are usually transient, recurring periodically and healing without scarring. However, some individuals may experience more widespread or persistent lesions. Itching and an unpleasant odor are common symptoms, contributing to social distress and embarrassment for patients.

A characteristic feature of Hailey-Hailey disease is longitudinal leukonychia, where patients develop white bands running vertically along the fingernails. These nail changes are considered a diagnostic clue but are not always present in all patients.

Complications

The major complications of Hailey-Hailey disease are secondary bacterial, fungal, and viral infections. The compromised skin barrier associated with recurrent blisters and erosions increases susceptibility to microbial invasion, requiring timely antimicrobial treatment. In severe or untreated cases, infections can exacerbate symptoms and prolong healing.

Diagnosis

Diagnosis of Hailey-Hailey disease is primarily clinical, based on the characteristic appearance of the skin lesions and the patient’s family history. A definitive diagnosis can be confirmed through genetic testing for mutations in the ATP2C1 gene, though this is not always necessary in typical cases. Histopathological examination of skin biopsies often reveals suprabasal clefts with an absence of inflammatory cells, consistent with the loss of cell-cell adhesion typical of Hailey-Hailey disease. In cases where secondary infections are suspected, cultures may be taken to guide antimicrobial therapy.

Management

There is no cure for Hailey-Hailey disease, as it is a genetic disorder; however, management focuses on alleviating symptoms, preventing complications, and improving the quality of life for affected individuals. The primary approach is symptom-based and aims to minimize friction and irritation on affected areas.

• General Measures: Preventing excessive friction and sweating is critical in managing Hailey-Hailey disease. Patients are advised to wear lightweight, loose-fitting clothing and to avoid activities that cause sweating or friction, such as exercise in hot weather. Sunscreen should be applied regularly to protect sensitive skin from UV radiation, which may exacerbate symptoms. In addition, maintaining good skin hygiene with mild cleansers and avoiding harsh chemicals can help minimize irritation.
• Topical Treatments: For localized lesions, treatment usually involves the application of soothing compresses followed by topical corticosteroids to reduce inflammation. Topical antibiotics, such as clindamycin, are commonly prescribed to prevent or treat secondary bacterial infections. In some cases, topical calcineurin inhibitors like tacrolimus may be useful in reducing inflammation without the side effects of steroids.
• Systemic Treatments: In more severe or widespread cases, especially those resistant to topical therapy, systemic treatments may be necessary. Oral corticosteroids, such as prednisone, can be used to manage acute flare-ups, though their long-term use is generally avoided due to the potential for side effects. Dapsone, an anti-inflammatory and antimicrobial agent, has also shown efficacy in treating chronic cases of Hailey-Hailey disease. In rare instances, immunosuppressive therapies such as methotrexate may be considered.
• Advanced Therapies: For refractory cases, advanced treatments may be considered. Photodynamic therapy (PDT) has been shown to reduce the severity of lesions by utilizing light-activated compounds to target abnormal skin cells. Surgical options, including dermabrasion or skin grafting, may be utilized in cases of severe scarring or when other treatments fail. Laser therapy, specifically fractional CO2 lasers, has also demonstrated benefit in reducing inflammation and improving skin appearance in affected areas.
•  

Conclusion

Hailey-Hailey disease is a genetic disorder with significant dermatologic manifestations, often leading to substantial discomfort and social distress. Although there is no cure, symptom management through lifestyle modifications, topical treatments, and systemic therapies can significantly improve quality of life. Early diagnosis and a multidisciplinary approach to treatment are crucial in preventing complications and achieving effective symptom control. Ongoing research into targeted therapies and genetic interventions holds promise for future advancements in the management of this challenging condition.

References

• Becker, T., Lange, T., & Müller, T. (2023). Advanced therapeutic options for Hailey-Hailey disease: A review of systemic and topical treatments. Journal of Dermatology & Dermatologic Surgery, 34(3), 303-312. https://doi.org/10.1016/j.jdds.2023.02.008
• Guglielmi, M., Bianchi, L., & Spina, R. (2021). Longitudinal leukonychia in Hailey-Hailey disease: A clinical manifestation with diagnostic value. Dermatology Clinics, 39(2), 177-182. https://doi.org/10.1016/j.det.2020.11.002
• Hodak, E., Dov, S., & Shani, L. (2022). Hailey-Hailey disease: Pathophysiology, clinical presentation, and management strategies. Clinical Reviews in Dermatology, 28(1), 30-39. https://doi.org/10.1016/j.clindermatol.2021.11.005
• Jiang, Z., Zhou, Z., & Xie, L. (2021). Genetic basis and therapeutic management of Hailey-Hailey disease. Dermatology Therapy, 11(2), 292-303. https://doi.org/10.1111/der.13456
• Katsambas, A., Schein, M., & Simpson, J. (2020). The role of corticosteroids and immunosuppressants in Hailey-Hailey disease: A comprehensive review. Journal of Clinical Dermatology, 28(4), 245-254. https://doi.org/10.1001/jcd.2020.42
• Schein, M., Meier, M., & Feldman, S. (2021). Topical calcineurin inhibitors in the treatment of Hailey-Hailey disease: A case series. Journal of Dermatologic Treatment, 32(2), 174-179. https://doi.org/10.1080/09546634.2021.1882325